Clinical trial
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
NCT06125522
Study timeline
Study start (actual)2024-01-10Date precision: day
Registry last updated2026-10-02
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
vepdegestrantDRUG · verified · RxNorm: vepdegestrant
SamuraciclibDRUG
Sponsors & collaborators
Pfizerlead sponsor
Arvinas Estrogen Receptor, Inc.collaborator
Carrick Therapeutics Limitedcollaborator
Rigel Pharmaceuticals,Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06125522 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.